EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
182 hedge funds and large institutions have $567M invested in Eagle Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 71 increasing their positions, 53 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
47% less capital invested
Capital invested by funds: $1.07B → $567M (-$501M)
48% less call options, than puts
Call options by funds: $3.18M | Put options by funds: $6.12M
Holders
182
Holding in Top 10
3
Calls
$3.18M
Puts
$6.12M
Top Buyers
| 1 | +$12.4M | |
| 2 | +$11M | |
| 3 | +$9.55M | |
| 4 |
D.E. Shaw & Co
New York
|
+$6.31M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$4.49M |
Top Sellers
| 1 | -$64.9M | |
| 2 | -$20.4M | |
| 3 | -$14.8M | |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$14.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.4M |